Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer

Phase 2 Completed 33 enrolled CASI pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the antitumor activity of MKC-1 in patients with unresectable or metastatic pancreatic cancer who have failed at least one prior chemotherapy regimen in either the neoadjuvant, adjuvant, or first-line metastatic setting

Timeline

Start: 2007-11
Primary completion: 2009-04
Completion: 2009-05

Publications

Results Faris JE, Arnott J, Zheng H, Ryan DP, Abrams TA, Blaszkowsky LS, Clark JW, Enzinger PC, Hezel AF, Ng K, Wolpin BM, Kwak EL. A phase 2 study of oral MKC-1, an inhibitor of importin-beta, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug;30(4):1614-20. doi: 10.1007/s10637-011-9708-3. Epub 2011 Jul 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MKC-1	Small molecule	100 mg/m2	Oral
Subject	MKC-1	Small molecule	150 mg	Oral

Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer

Summary

Timeline

Publications

Drugs

Indications